Skip to main content
78°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Altamira Therapeutics
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
June 29, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
June 27, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Tickers
CYTO
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
June 23, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
June 09, 2022
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Tickers
CYTO
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray
June 08, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia
May 31, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
May 23, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Tickers
CYTO
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
May 20, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
May 19, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Therapeutics Issues Shareholder Letter
May 18, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
May 05, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
April 19, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
April 12, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
April 11, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
April 04, 2022
From
Altamira Therapeutics
Via
AccessWire
Topics
Earnings
Exposures
Financial
Tickers
CYTO
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
March 15, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
March 11, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
March 09, 2022
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
March 04, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
February 14, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
February 09, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
February 07, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
February 04, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
January 21, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Provides Update on RNA Therapeutics Program
January 13, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
January 05, 2022
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Provides Update on Bentrio Program
December 29, 2021
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
CYTO
Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy
December 16, 2021
From
Altamira Therapeutics
Via
AccessWire
Tickers
CYTO
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis
December 01, 2021
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Tickers
CYTO
Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021
November 15, 2021
From
Altamira Therapeutics
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
Death
Intellectual Property
Legal
Tickers
CYTO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.